References
- Kim EK, Youn YS, Rhim JW, Shin MS, Kang JH, Lee KY. Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years. Korean J Pediatr 2015;58:172-7. https://doi.org/10.3345/kjp.2015.58.5.172
- Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008;6:509-21. https://doi.org/10.1586/14787210.6.4.509
- Hegde S, Hegde S, Spergser J, Brunthaler R, Rosengarten R, Chopra-Dewasthaly R. In vitro and in vivo cell invasion and systemic spreading of Mycoplasma agalactiae in the sheep infection model. Int J Med Microbiol 2014;304:1024-31. https://doi.org/10.1016/j.ijmm.2014.07.011
- Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2012;55:42-7. https://doi.org/10.3345/kjp.2012.55.2.42
- Hong KB, Choi EH, Lee HJ, Lee SY, Cho EY, Choi JH, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis 2013;19:1281-4. https://doi.org/10.3201/eid1908.121455
- Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in nonsevere community acquired pneumonia: meta-analysis. BMJ 2005;330:456. https://doi.org/10.1136/bmj.38334.591586.82
- Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for communityacquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 2015;1: CD004875.
- Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41:263-8. https://doi.org/10.1002/ppul.20374
- Takei T, Morozumi M, Ozaki H, Fujita H, Ubukata K, Kobayashi I, et al. Clinical features of Mycoplasma pneumoniae infections in the 2010 epidemic season: report of two cases with unusual presentations. Pediatr Neonatol 2013;54:402-5. https://doi.org/10.1016/j.pedneo.2012.11.016
- Yang HJ, Song DJ, Shim JY. Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2017;60:167-74. https://doi.org/10.3345/kjp.2017.60.6.167
- Lee KY. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. Int J Mol Sci 2017;18(2). pii: E388. https: //doi.org/10.3390/ijms18020388.
- Denny FW, Clyde WA Jr, Glezen WP. Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control. J Infect Dis 1971;123:74-92. https://doi.org/10.1093/infdis/123.1.74
- Hirao S, Wada H, Nakagaki K, Saraya T, Kurai D, Mikura S, et al. Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone. FEMS Immunol Med Microbiol 2011;62:182-9. https://doi.org/10.1111/j.1574-695X.2011.00799.x
- Becker A, Kannan TR, Taylor AB, Pakhomova ON, Zhang Y, Somarajan SR, et al. Structure of CARDS toxin, a unique ADP-ribosylating and vacuolating cytotoxin from Mycoplasma pneumoniae. Proc Natl Acad Sci U S A 2015;112:5165-70. https://doi.org/10.1073/pnas.1420308112
- Lee KY. A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis. Infect Chemother 2015;47:12-26. https://doi.org/10.3947/ic.2015.47.1.12
- Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, Lee JS, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr 2010;10:48. https://doi.org/10.1186/1471-2431-10-48
- Youn YS, Lee SC, Rhim JW, Shin MS, Kang JH, Lee KY. Early additional immune-modulators for Mycoplasma pneumoniae pneumonia in children: an observation study. Infect Chemother 2014;46:239-47. https://doi.org/10.3947/ic.2014.46.4.239
- You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res 2014;6:22-6. https://doi.org/10.4168/aair.2014.6.1.22
- Rhim JW, Lee KY, Youn YS, Kang JH, Kim JC. Epidemiological and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: an observational cohort study. BMC Infect Dis 2011;11:225. https://doi.org/10.1186/1471-2334-11-225
- Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebocontrolled trial. Lancet 2015;385:1511-8. https://doi.org/10.1016/S0140-6736(14)62447-8
- Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677-86. https://doi.org/10.1001/jama.2015.88
Cited by
- Emerging Antibiotic Resistance in Mycoplasma Microorganisms, Designing Effective and Novel Drugs / Therapeutic Targets: Current Knowledge and Futuristic Prospects vol.13, pp.1, 2017, https://doi.org/10.22207/jpam.13.1.03
- Correlation between Cytokine and Chemokine levels and Clinical Severity in Children with Mycoplasma pneumoniae Pneumonia vol.26, pp.1, 2017, https://doi.org/10.14776/piv.2019.26.e6
- Mycoplasma pneumoniae ‐induced rash and mucositis is a distinct entity that needs more recognition vol.56, pp.4, 2020, https://doi.org/10.1111/jpc.14625
- Macrolide-Resistant and Macrolide-Sensitive Mycoplasma pneumoniae Pneumonia in Children Treated Using Early Corticosteroids vol.10, pp.6, 2017, https://doi.org/10.3390/jcm10061309